A New Risk

With the 2020 Presidential campaign already underway it might be time for all the insulin companies to be paying very careful attention. The drumbeat about the high cost of insulin continues while earlier this month per a press release;

“U.S. Representative Bobby L. Rush (D-Ill.) introduced H.R.366, the Insulin Access for All Act of 2019. This bill, cosponsored by 33 members of the House Democratic Caucus, eliminates the cost sharing requirement under Medicare and Medicaid for insulin.”

A day does not go by without one story or another, usually on social media, about patients rationing their . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.